NAPP PHARMACEUTICAL GROUP LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company's business activities, together with the factors likely to affect its future development, are described in the Strategic Report. The Company is a member of the Napp Pharmaceutical Holdings Limited group, and is subject to the overall financing arrangements of the group. As such the Company has received a formal letter of support from the Company's parent undertaking, guaranteeing continued financial support to enable the Company to meet its liabilities to creditors as they fall due for the period to 31 August 2026. The directors have assessed that the group has sufficient resources to provide such support notwithstanding the risks and uncertainties disclosed in the group consolidated financial statements. The Company, through its group activities, expects to see continued demand for its product portfolio, which notably contains many well-established products treating chronic conditions. The group's latest financial projections show that the group remains in a strong position to support the Company through to 31 August 2026. Based on this assessment the directors continue to adopt the going concern basis in preparing the annual report and accounts.”

Group structure

1. NAPP PHARMACEUTICAL GROUP LIMITED · parent
   1. Napp Laboratories Limited 100% · supply of pharmaceutical products
   2. Bard Pharmaceuticals Limited 100% · manufacture of pharmaceutical products
   3. Napp Research Centre Limited 100% · non-trading

Significant events

• “On 24 April 2024, the Company acquired all of Cidara Therapeutic's rights related to Rezafungin globally for nil consideration. The Company acquired the rights to future royalties and milestone payments as well as the obligations to fund ongoing development costs. The fair value of net assets acquired was £51,278,000 resulting in negative goodwill of £51,278,000.”
• “On 8 August 2024, the board agreed to extend the unsecured loan of $43.5m to a related party to 14 November 2024 and amend the interest rate to 5.83% per annum. The amendments became effective on 14 August 2024. The loan was subsequently repaid on 15 November 2024.”
• “On 02 July 2025, the Board of the Company declared an interim dividend distribution of $6,583 equivalent to £4,818.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +21.2%

  £16,741,000 → £20,290,000

• Cash

  -99.5%

  £7,887,000 → £39,000

• Net assets

  +2.2%

  £131,503,000 → £134,447,000

• Employees

  —

  Not reported

• Operating profit

  -75.8%

  £8,690,000 → £2,105,000

• Profit before tax

  -60.7%

  £9,995,000 → £3,925,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers